Disease Activity Criteria Impact Dosing Interval Assignment in Neovascular Age-related Macular Degeneration Trials

Affiliations

¹ Rutgers New Jersey Medical School, Newark, New Jersey. Electronic address: zarbin@umdnj.edu.
² Baylor College of Medicine, Cullen Eye Institute, Houston, Texas.
³ Retina Consultants San Diego, San Diego, California.
⁴ Camden Medical Centre, Singapore, Singapore.
⁵ Ophthalmology, Hospital Universitario La Fe, Valencia, Spain.
⁶ Department of Surgery, McMaster University, Hamilton, Ontario, Canada; Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada.
⁷ F. Hoffmann-La Roche Ltd, Basel, Switzerland.
⁸ Genentech, Inc., South San Francisco, California.

Free article

Marco A Zarbin et al. Ophthalmol Retina. 2025 Apr.

Free article

. 2025 Apr;9(4):404-407.

doi: 10.1016/j.oret.2024.12.021. Epub 2024 Dec 27.

¹ Rutgers New Jersey Medical School, Newark, New Jersey. Electronic address: zarbin@umdnj.edu.
² Baylor College of Medicine, Cullen Eye Institute, Houston, Texas.
³ Retina Consultants San Diego, San Diego, California.
⁴ Camden Medical Centre, Singapore, Singapore.
⁵ Ophthalmology, Hospital Universitario La Fe, Valencia, Spain.
⁶ Department of Surgery, McMaster University, Hamilton, Ontario, Canada; Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada.
⁷ F. Hoffmann-La Roche Ltd, Basel, Switzerland.
⁸ Genentech, Inc., South San Francisco, California.

No abstract available

Keywords: Criteria; Disease Activity; Durability; Faricimab; Neovascular age-related macular degeneration.

LinkOut - more resources